AX-158
Plaque Psoriasis
Key Facts
About Artax Biopharma
Artax Biopharma is pioneering a new class of immunomodulators targeting the Nck protein to treat autoimmune diseases by rebalancing, rather than suppressing, the immune system. The company's lead asset, AX-158, is in Phase 2 development for psoriasis, with plans to expand into atopic dermatitis and rheumatoid arthritis. Founded in 2015 and led by an experienced management team, Artax aims to address a significant unmet need in autoimmunity with a potentially safer, more targeted therapeutic profile. Its technology platform offers a differentiated mechanism that could be applicable across multiple T-cell mediated conditions.
View full company profileAbout Artax Biopharma
Artax Biopharma is pioneering a new class of immunomodulators targeting the Nck protein to treat autoimmune diseases by rebalancing, rather than suppressing, the immune system. The company's lead asset, AX-158, is in Phase 2 development for psoriasis, with plans to expand into atopic dermatitis and rheumatoid arthritis. Founded in 2015 and led by an experienced management team, Artax aims to address a significant unmet need in autoimmunity with a potentially safer, more targeted therapeutic profile. Its technology platform offers a differentiated mechanism that could be applicable across multiple T-cell mediated conditions.
View full company profileAbout Artax Biopharma
Artax Biopharma is pioneering a new class of immunomodulators targeting the Nck protein to treat autoimmune diseases by rebalancing, rather than suppressing, the immune system. The company's lead asset, AX-158, is in Phase 2 development for psoriasis, with plans to expand into atopic dermatitis and rheumatoid arthritis. Founded in 2015 and led by an experienced management team, Artax aims to address a significant unmet need in autoimmunity with a potentially safer, more targeted therapeutic profile. Its technology platform offers a differentiated mechanism that could be applicable across multiple T-cell mediated conditions.
View full company profileTherapeutic Areas
Other Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Piclidenoson (CF101) | Can Fite Biopharma | Phase III |
| Psoriasis Trial | Clinical Investigation Specialists | Not Specified |
| Encube-001 | Encube Ethicals | Phase 1/2a |
| ZL-1102 (CB001) | Crescendo Biologics | Phase 2 |
| NG-303 | Nanogen Pharmaceutical Biotechnology | Preclinical |
| Pepticom‑IL17 | Pepticom | Lead Optimization |
| JNJ-2113 | Johnson & Johnson | Phase 3 |
| VTAMA® (tapinarof) | Roivant Sciences | Approved |
| Wynzora | Almirall | Marketed |
| JNJ-81201887 (via Janssen) | OmniAb | Approved |